According to The Wall Street Journal, a study touting the success of HeartWare International Inc.’s heart pump has made the company a potential target for acquisition by larger medical device companies.
The American Heart Association reported the findings of a study over a weekend meeting, which demonstrated good future prospects for sales of HeartWare’s HVAD. The 5-ounce implantable pump was shown to lengthen the lives of patients with heart failure. Patients who received an HVAD had a 92 percent survival rate after 6 months.
One in five Americans older than 40 has heart failure. The disease is progressive and results in a lack of oxygen reaching other organs in the body. There is no cure. According to the WSJ, the U.S. market for devices to extend people’s lives with heart failure could be at least a $4.5 billion market.
The device is described by analysts interviewed by the WSJ as a potential growth opportunity for large medical companies in the cardiac device market. The company had record gains in the price of its shares in Nasdaq trading. HeartWare shares rose 23 percent on Monday morning, from $16.73 to $88.99.
HeartWare International Rises as Heart Pump Study Sparks Talk of a Merger (Bloomberg)